Enhanced expression of complement and microglial-specific genes prior to clinical progression in the MOG-experimental
Pierre Becquart1, Carles Vilariño-Güell2, Jacqueline A Quandt1
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Abstract:
Understanding the biological changes responsible for failures in repair and the development of progressive MS is paramount for therapeutic intervention. In a well characterized experimental autoimmune encephalomyelitis (EAE) model of MS the clinical phenotype features an acute attack with partial recovery followed by a chronic or progressive disease phase. Neuropathology-focused gene expression profiles were generated from spinal cord, hindbrain and forebrain of mice 25 days after the induction of EAE, the time when recovery plateaus and transitions to a chronic or worsening phase. Differences in gene expression were most pronounced in the spinal cord of EAE mice compared to sham-immunized animals, with a subset of genes also found to be differentially expressed in the hindbrain and the forebrain, albeit with smaller fold-changes in expression. Our data suggests that changes in complement components, chemoattractant cytokines and especially enrichment in microglial cells may be the primary drivers of processes that limit recovery in EAE.
Insights
Investigating gene expression in a multiple sclerosis (MS) mouse model reveals that microglial cell enrichment and altered complement components may hinder repair and drive progressive disease, impacting therapeutic strategies.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Multiple sclerosis (MS) is characterized by progressive neurodegeneration and repair failure.
- The experimental autoimmune encephalomyelitis (EAE) model mimics MS, showing acute phases followed by chronic progression.
- Understanding molecular drivers of MS progression is crucial for developing effective therapies.
Purpose of the Study:
- To identify key biological changes underlying repair failure and progressive disease in the EAE model.
- To analyze gene expression profiles at a critical transition point from recovery to chronic MS.
- To pinpoint molecular pathways and cell types involved in limiting recovery.
Main Methods:
- Generation of neuropathology-focused gene expression profiles from spinal cord, hindbrain, and forebrain of EAE mice.
- Comparison of gene expression between EAE mice and sham-immunized controls at 25 days post-induction.
- Analysis of differential gene expression to identify key molecular players.
Main Results:
- Significant gene expression differences were observed in the spinal cord of EAE mice.
- A subset of genes showed differential expression in the hindbrain and forebrain, though with smaller changes.
- Key changes involved complement components, chemoattractant cytokines, and a notable enrichment of microglial cells.
Conclusions:
- Microglial cell enrichment and altered complement/cytokine pathways are implicated as primary drivers limiting recovery in EAE.
- These findings provide insights into the biological mechanisms behind progressive MS.
- Identifying these drivers is essential for future therapeutic interventions targeting MS progression.
More Related Videos
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
08:03Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014